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ABSTRACT 
Background & Aims: Focal zone 1 steatosis, although rare in adults with nonalcoholic 
fatty liver disease (NAFLD), does occur in children with NAFLD. We investigated 
whether focal zone 1 steatosis and focal zone 3 steatosis are distinct subphenotypes of 
pediatric NAFLD. We aimed to determine associations between the zonality of steatosis 
and demographic, clinical, and histologic features in children with NAFLD.  
Methods: We performed a cross-sectional study of baseline data from 813 children 
(age less than 18 years; mean age, 12.8±2.7 years). The subjects had biopsy-proven 
NAFLD and were enrolled in the NASH Clinical Research Network. Liver histology was 
reviewed using the Nonalcoholic Steatohepatitis Clinical Research Network scoring 
system. 
Results: Zone 1 steatosis was present in 18% of children with NAFLD (n=146) and 
zone 3 steatosis was present in 32% (n=244). Children with zone 1 steatosis were 
significantly younger (10 vs 14 years; P<.001) and a significantly higher proportion had 
any fibrosis (81% vs 51%; P<.001) or advanced fibrosis (13% vs 5%; P<.001) compared 
to children with zone 3 steatosis. In contrast, children with zone 3 steatosis were 
significantly more likely to have steatohepatitis (30% vs 6% in children with zone 1 
steatosis; P<.001). 
Conclusion: Children with zone 1 or zone 3 distribution of steatosis have an important 
sub-phenotype of pediatric NAFLD. Children with zone 1 steatosis are more likely to 
have advanced fibrosis and children with zone 3 steatosis are more likely to have 
steatohepatitis. In order to achieve a comprehensive understanding of pediatric NAFLD, 
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studies of pathophysiology, natural history, and response to treatment should account 
for the zonality of steatosis.  
 
KEY WORDS: NASH; pediatric; disease progression; obesity 
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Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in 
children, with an estimated prevalence of 9.6% in the United States 1. NAFLD 
encompasses a spectrum of severity ranging from isolated steatosis to nonalcoholic 
steatohepatitis (NASH) with or without fibrosis. The histologic triad of classically 
described NASH in adults includes fat accumulation in hepatocytes, inflammation, and 
liver injury as manifest by hepatocyte ballooning 2. These same features can be 
identified in the livers of children with NAFLD, but there are distinct differences in the 
microscopic appearance in many pediatric cases. Specifically, children with fatty liver 
disease may have more steatosis, fewer ballooned hepatocytes and more portal-based 
inflammation and/or fibrosis 3.   
 
Studies of steatosis in the context of NASH to date have focused largely on the amount 
of steatosis. For example, in a study in adults with NAFLD from the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK) Nonalcoholic Steatohepatitis 
Clinical Research Network (NASH CRN), Neuschwander-Tetri et al found that those 
with moderate and severe steatosis were more likely to have NASH than those with only 
mild steatosis 4. In addition, in a study of children from the NASH CRN, children with 
hypertension tended to have more steatosis compared to those who were normotensive 
5
. Another study of adults with NAFLD showed that those with type 2 diabetes had more 
severe steatosis on histology compared to those without diabetes 6. 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
In addition to the percentage of hepatocytes with steatosis, steatosis can be categorized 
based on the hepatic zones in which fat droplets are present. Fat accumulation in 
hepatocytes may be microscopically subdivided in four distributions, regardless of 
amount: panacinar (even distribution), zone 1 (periportal), zone 3 (centrilobular or 
pericentral), and azonal (uneven distribution) (see figure 1). Previous research has 
shown that in adults with NAFLD, inflammation and fibrosis tend to be in zone 3 and not 
in zone 1. This is in contrast to children, in which inflammation and fibrosis are often 
present in zone 1, but can be seen in zone 3. Much less is known about the localization 
of steatosis in NAFLD than the localization of inflammation or fibrosis. Previous studies 
have shown about 10 percent of children have accentuation of steatosis in periportal, or 
zone 1, hepatocytes 3,7,8, whereas, zone 1 steatosis is uncommon in adults with NAFLD 
8,9
. Thus, clinical correlates of zone 1 versus zone 3 steatosis are relatively unexplored, 
and in order to do so would require a large population of children with biopsy-proven 
NAFLD. The NIH NASH CRN provides such a cohort as biopsy evaluation includes 
localization as well as amount of steatosis, and we therefore performed a multi-center, 
cross-sectional cohort study from this cohort with the aim of determining associations 
between zone 1 and zone 3 localizations of steatosis and demographic, clinical, and 
other histologic features in children with NAFLD. In addition to the percentage of 
hepatocytes with steatosis, steatosis can be categorized based on the hepatic zones in 
which fat droplets are present. Fat can accumulate in hepatocytes in four distributions: 
panacinar, zone 1 (periportal), zone 3 (centrilobular or pericentral), and azonal (see 
figure 1). Previous research has shown that in adults with NAFLD, inflammation and 
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fibrosis tend to be in zone 3 and not in zone 1. This is in contrast to children, in which 
inflammation and fibrosis are often present in zone 1, but can be seen in zone 3. Much 
less is known about the localization of steatosis in NAFLD than the localization of 
inflammation or fibrosis. Previous studies have shown about 10 percent of children have 
accentuation of steatosis in periportal, or zone 1, hepatocytes 3,7,8, whereas, zone 1 
steatosis is uncommon in adults with NAFLD 8,9. Thus, clinical correlates of zone 1 
versus zone 3 steatosis are relatively unexplored, and in order to do so would require a 
large population of children with biopsy-proven NAFLD. The NIH NASH CRN provides 
such a cohort, and we therefore performed a multi-center, cross-sectional cohort study 
with the aim of determining associations between zone 1 and zone 3 localization of 
steatosis and demographic, clinical, and other histologic features in children with 
NAFLD. 
 
METHODS 
Study Population  
We included children < 18 years of age with NAFLD enrolled in the NASH CRN who 
were participants in one of the following studies: the longitudinal cohort studies 
Database and Database 2 (NCT01061684) or the randomized controlled trials 
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) (NCT00063635) or 
Cysteamine Bitartrate Delayed-Release for the Treatment of Non-alcoholic Fatty Liver 
Disease in Children (CyNCh) (NCT01529268). The diagnosis of NAFLD was based on 
≥ 5% of hepatocytes containing macrovesicular fat and exclusion of other causes of 
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chronic liver disease based on clinical history, laboratory studies, and histology8. The 
institutional review board at each participating center approved these studies. Written 
consent was obtained from each participant’s parent or guardian, and written assent 
was obtained from each participant age 8 and older.   
 
History and Physical Examination 
Demographic data and clinical history were obtained via a structured interview 
developed by the NASH CRN.  Weight and height were measured to the nearest 0.1 kg 
and 0.1 cm, respectively. BMI was calculated as weight (kg) per height (m) squared.  
BMI Z-score was calculated to account for age and sex and based on Center for 
Disease Control and Prevention reference standards.  
 
Laboratory Studies 
Participants fasted for 12 hours prior to collection of blood via venipuncture. Laboratory 
assays included: aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
gamma-glutamyltransferase (GGT), total cholesterol, high-density lipoprotein (HDL), 
low-density lipoprotein (LDL), triglycerides, hemoglobin A1C, serum glucose, and serum 
insulin.    
 
Liver Histology  
The Pathology Committee of the NASH CRN reviewed H&E and trichrome stained 
slides in consensus conference according to the NASH CRN scoring system8. The 
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pathologists were unaware of the clinical study, age, gender or other clinical features of 
the children at the time of review, including whether the biopsy was from a child or adult. 
Biopsies were given a score for degree of steatosis based on the following: grade 0 
(none to <5%), grade 1 (5% to 33%), grade 2 (34% to 66%), and grade 3 (>66%).   
Lobular inflammation was categorized based on the assessment of all inflammatory foci: 
no foci, <2 foci per 200x field, 2-4 foci per 200x field, and >4 foci per 200x. Portal 
inflammation was categorized into three groups: none, mild, and more than mild. 
Ballooning was categorized into three groups: none, few, and many.  Fibrosis was 
staged based on the following: stage 0 (no fibrosis), stage 1a (mild zone 3 
perisinusoidal requiring trichrome stain), stage 1b (moderate zone 3 perisinusoidal 
fibrosis not requiring trichrome stain), stage 1c (portal/periportal fibrosis only), stage 2 
(zone 3 perisinusoidal and periportal), stage 3 (bridging fibrosis), and stage 4 (cirrhosis).  
An overall diagnosis was made based on the composite features of the biopsy, but 
without regard to NAFLD Activity Score, according to the following categories: NAFLD 
not NASH, borderline zone 1 NASH, borderline zone 3 NASH, and definite NASH. 
Location of steatosis was noted as follows: zone 1 (periportal), zone 3 (perivenular), 
panacinar and azonal. Azonal (irregular) distribution of fat droplets was assigned to 
cases in two circumstances: 1) when clear zone 1, zone 3, or uniform panacinar 
patterns of steatosis were not apparent or 2) when cirrhosis or bridging fibrosis were 
present, as vascular landmarks are lost. Panacinar steatosis was recorded when there 
was an even distribution, regardless of amount, throughout the lobule and with no 
predilection for, or sparing of zones. The NAFLD Activity Score (NAS) was 
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subsequently calculated from the scores assigned for steatosis amount, lobular 
inflammation and ballooning, as described 8. 
 
Data Analysis 
For this analysis, only cases with pure zone 1 and zone 3 steatosis were compared. 
The demographic, clinical, and histopathological characteristics of all children included 
in this study were reported using standard descriptive statistics. Children were divided 
into two groups for analysis: those with zone 1 steatosis and those with zone 3 
steatosis. For continuous variables, sample mean, standard deviation, and 95% 
confidence interval were calculated. Wilcoxon Rank test and two-sample t-test were 
used to compare demographic and laboratory continuous parameters among the two 
groups. For categorical variables, frequency and percentages were computed. Chi-
square test was used to compare differences between the groups for binary categorical 
variables. Mantel-Haenszel Chi-Square Test was used to compare differences between 
the groups for ordinal categorical variables. Demographic factors influencing the 
presence of zone 1 and zone 3 steatosis were identified using multinomial logistic 
regression models, with presence of Zone 1 and Zone 3 as primary outcomes and 
candidate factors: age, sex, ethnicity, and BMI Z-score. Goodness of fit of the first 
logistic regression model (zone 1 vs other distributions) was assessed using a Hosmer-
Lemeshow chi-square test with p>0.05 indicating adequate fit. The likelihood ratio test, 
Score test, and Wald test assessed the fit of the model compared to an empty model. 
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Parallel analysis was done with the second logistic regression model (zone 3 vs other 
distributions). Analyses were performed using SAS version 9.4 and R version 3.2.3. 
 
RESULTS 
Study Population 
There were 813 children enrolled in the NASH CRN.  Thirty-seven children were 
excluded because their liver biopsy results were not consistent with NAFLD. In the 
remaining 776 children, the zonality of steatosis in the liver biopsies was distributed as 
follows: zone 1=146 (19%), zone 3=244 (31%), azonal=59 (8%), panacinar=327 (42%). 
The remainder of data pertain to zone 1 and zone 3 steatosis cohorts; data for the 
panacinar and azonal cohorts are available in Supplemental Tables 1 and 2.  
 
Demographic and Clinical Differences between Zone 1 and Zone 3 Steatosis 
Cohorts 
Demographic and clinical parameters are shown in Table 1 for the 390 children with 
zone 1 or zone 3 steatosis. As shown in Figure 2, children with zone 1 steatosis were 
younger than children with zone 3 steatosis (mean age 10.8 (SD 2.1) vs 14.7 (SD 2.1) 
years, p<0.001). Children with zone 1 steatosis were more likely to be Hispanic (75% vs 
58%, p=0.001) than those with zone 3 steatosis.  Children with zone 1 steatosis had 
higher fasting triglyceride levels (164 vs 125 mg/dL, p<0.001) and lower fasting insulin 
(25 vs 39 µU/mL, p<0.001) than those with zone 3 steatosis. There was no significant 
difference in sex between children with zone 1 and zone 3 steatosis. Height, weight and 
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BMI were all significantly different between zonality group, but BMI Z-score was not. 
Children with zone 3 steatosis had higher waist circumference (109.5 vs 96.4 cm, p 
<0.001), systolic blood pressure (125 vs 115 mmHg, P<0.001), and diastolic blood 
pressure (70 vs 65 mmHg, p<0.001) than those with zone 1 steatosis. There were no 
significant differences in ALT or GGT between groups, but there was a small but 
significant difference in AST, with those in Zone 1 steatosis group having higher AST 
(56 vs 52 U/L, p=0.017).  
 
Histological Differences between Zone 1 and Zone 3 Steatosis 
As shown in Table 2, there were distinct histological differences between the zone 1 
and zone 3 steatosis groups, although the grades of steatosis did not differ for children 
with zone 1 or zone 3 steatosis. Biopsies with zone 3 steatosis had more ballooning 
compared to those with zone 1 steatosis (48% vs 29%, p<0.001), higher NAS score (4.1 
vs 3.7, p=0.014), and a greater frequency of a diagnosis of definite NASH than biopsies 
with zone 1 steatosis (30% vs 6%, p<0.001). Biopsies with zone 1 steatosis had more 
portal inflammation than those with zone 3 steatosis (97% vs 75%, p<0.001). In 
univariate analysis, biopsies with zone 1 steatosis compared to biopsies with zone 3 
steatosis had more fibrosis of any grade (80% vs 51%) and more advanced fibrosis 
(13% vs 5%) (p<0.001). In a multivariate logistic regression model, after controlling for 
age, sex, and BMI Z-score, children with zone 1 steatosis had 2.34 times the odds of 
having advanced fibrosis than children with zone 3 steatosis (95 CI 1.03-5.52).  
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Logistic Regression Model for Zone 1 and Zone 3 Steatosis 
Among all children with NAFLD, the only independent risk factor identified for having 
zone 1 steatosis was age. Specifically, children < 13 years had 6.3 (95 CI 3.9-10.4) 
times the odds of having zone 1 steatosis compared to children ≥ 13 years. In contrast, 
both age and sex were significant independent risk factors for having zone 3 steatosis. 
Thus, children with NAFLD who were ≥ 13 years had 9.0 (95 CI 6.3-13.2) times the 
odds of having zone 3 steatosis compared to children less than 13 years. In addition, 
girls with NAFLD had 1.6 (95 CI 1.1-2.3) times the odds of having zone 3 steatosis 
compared to boys with NAFLD. Ethnicity and BMI Z-score did not improve the fit of the 
model for either zone 1 or one 3 steatosis.  
 
Subanalysis of Zone 3 Steatosis with Either Zone 1 or Zone 3 Fibrosis 
Within the defined patterns of zonality of steatosis, there was a noted distribution of 
fibrosis, central/perisinusoidal and portal. As shown in Table 2, 94 (64%) biopsies with 
zone 1 steatosis had fibrosis that co-localized with the steatosis, with only 3 (3%) in this 
group having central/perisinusoidal fibrosis. Thus, due to the small number, this was not 
analyzed further.  
 
In contrast, for those with zone 3 steatosis, 75 (31%) had fibrosis that was zonally 
restricted, and 24 (32%) of these had a portal fibrosis pattern. Therefore, we further 
analyzed differences of fibrosis patterns among children with biopsies showing zone 3 
steatosis. As shown in Table 3, children with zone 3 steatosis and portal fibrosis were 
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younger than those who had zone 3 steatosis with central fibrosis (14.1 vs 15.7 years, 
p=0.0142).  In addition, there was a significant difference in ALT, with the central fibrosis 
group having higher mean ALT than the portal fibrosis group (97 U/L vs 56 U/L, 
p=0.0003).  As expected, the portal fibrosis group had significantly more portal 
inflammation than the central fibrosis group (92% vs 78%, p=0.0112). There were also 
more children in the central fibrosis group with a diagnosis of definite NASH (55% vs 
8%) and borderline zone 3 NASH (43% vs 12.5%) than the portal fibrosis group. There 
were more children in the portal fibrosis group that had borderline zone 1 NASH (17% 
vs 0%) (p<0.0001). There were no significant differences in sex, ethnicity, BMI Z-score, 
or steatosis grade between central and portal fibrosis groups.  
 
DISCUSSION 
We studied the zonal distribution of hepatic steatosis in a large cohort study of children 
with NAFLD from pediatric centers across the United States.  Steatosis was confined to 
zone 1 or zone 3 in approximately half of biopsies with NAFLD.  Age and sex were the 
major demographic characteristics that were associated with the zonal location of 
steatosis. Children with zone 1 steatosis were younger and more likely to be boys by 
logistic regression. Other associations with zone 1 steatosis were Hispanic ethnicity, 
higher AST and triglyceride levels, and lower insulin levels. Finally, biopsies with zone 1 
steatosis were more likely to have fibrosis. In contrast, biopsies from children with zone 
3 steatosis more frequently showed ballooning and were more likely to be diagnosed as 
definite NASH.  
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This cross-sectional study affirms the importance of steatosis zonality in the 
characterization of pediatric NAFLD. To distinguish classically described steatohepatitis 
10,11
 from a newly recognized pediatric zone 1 pattern, Schwimmer et al characterized 
Zone 3 predominant disease as "Type 1 NASH" and the Zone 1 predominant pattern as 
Type 2 NASH 3.  In the current study, those children whose biopsies had zone 3 
steatosis were similar to children with Type 1 NASH, namely older and less likely to be 
boys, while those with zone 1 steatosis were similar to the children categorized as Type 
2 NASH, namely younger and with greater male predominance. These differences in 
zonality may have clinical implications, associated with alterations in insulin levels and 
triglyceride concentrations, and also possibly advanced fibrosis that can ultimately result 
in worsening liver function.  
 
The hedgehog and Wnt/beta-catenin pathways may explain localization of steatosis to 
Zone 1 and Zone 3. The hedgehog pathway has higher activity in young children and 
lower activity in adulthood and has high activity in the portal/periportal region 12–14. This 
pathway is implicated in the development of fibrosis and cirrhosis in both animals and 
humans 14. This is in contrast to the Wnt/beta-catenin pathway, which becomes more 
active with age, very low in early development and more active in adulthood 15. This 
pathway has the highest canonical activity around the terminal hepatic venules and 
governs pathways involving glutamine synthesis, drug metabolism, bile acid, and heme 
synthesis 16. In addition, it is involved in hepatic development, regeneration, and 
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response to oxidative stress. In murine models, pericentral steatosis with periportal 
sparing was found in beta-catenin transgenic mice given a high-fat diet, while beta-
catenin knockout mice had periportal steatosis with perivenous sparing 17,18. The 
presence of zone 1 steatosis in younger patients could relate to immature or absent 
beta catenin pathway activity, while hedgehog pathway activity may be a potential clue 
why fibrosis was more common among children with zone 1 steatosis. These pathways 
may be potential targets of therapy.  
 
In our study, children with zone 3 steatosis were older and had higher circulating insulin 
levels compared to those with zone 1 steatosis. Increased fasting insulin levels are 
often seen with metabolic syndrome. In the setting of metabolic syndrome, hepatocytes 
in zone 3 increasingly engage in glycolysis and de novo lipogenesis (DNL) resulting in a 
higher presence of zone 3 steatosis given that the activity of specific enzymes involved 
in DNL, such as ATP citrate lyase, acetyl-CoA carboxylase, and fatty acid synthase, are 
higher in zone 3 hepatocytes 19,20. here is also higher expression of triacylglycerol 
synthetic enzyme, triacylglycerol hydrolase, in zone 3 hepatocytes 21,22. We therefore 
speculate that these findings may indicate that the zone 3 steatosis pattern may be 
consistent with higher zone 3 DNL and lower VLDL export.  
 
Importantly, localization of the fat droplets in the liver requires histology.  Although AST 
levels were statistically different between children with Zone 1 or Zone 3 steatosis, the 
difference observed was not sufficient to allow stratification of steatosis by zone. There 
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were statistically significant differences with waist circumference and blood pressure as 
well, though both of these are intimately related to age; older children will have higher 
waist circumferences and blood pressures. Also of note, there was no relationship 
between the severity of steatosis and the zonality of fat, making current imaging 
modalities unhelpful for this characterization. Clinically, there may be a reluctance to 
perform biopsies on children suspected to have NAFLD, though liver biopsies are safe 
and can help in the diagnosis of NASH and other causes of hepatitis with hepatic 
steatosis23. In post-hoc analysis of a recent study by the NASH CRN, there was 
significant histologic improvement in children with Borderline Zone 1 NASH compared to 
placebo. This is in contrast to those with other types of NASH, showing that there may 
be a difference in response to treatment based on zonation24. Hence, there are potential 
implications for the utility of biopsies for individual patients.  
 
The characterization of subphenotypes of NAFLD based on zonality of steatosis is 
strengthened by the use of the NASH CRN, the largest prospective cohort of children 
with NAFLD in the U.S. The diagnosis of NAFLD subtype and specification of steatosis 
zonality were done in a standardized fashion blinded to submitting center or patient age, 
along with all features of biopsy analysis by the Pathology Committee.  Although the 
method of analysis utilized does not result in a final score that highlights zonality, there 
are two features of the NASH CRN pathology method that can be suggestive of a 
pediatric pattern of NAFLD: the portal-based pattern of fibrosis (1c), and the diagnostic 
subtype, borderline zone 1.  In this study, a subset of children had steatosis and fibrosis 
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in different zones. It remains unclear how zonation of steatosis, along with inflammation 
and the development of fibrosis, change over time due to the cross-sectional nature of 
this study. Longitudinal studies are important to address questions regarding the 
development as well as the stability or instability of steatosis localization.   
 
Conclusion: Zone 1 and zone 3 steatosis are two distinct subphenotypes of pediatric 
NAFLD that may be informative of risk differences in the progression of NAFLD, namely 
in terms of advanced fibrosis and steatohepatitis, respectively.  Further work is needed 
to analyze the natural history and long-term outcomes associated with these steatosis 
zonality patterns as children grow and develop.  A better understanding of the 
pathophysiologic differences between these steatosis zonality patterns may provide 
opportunities for targeted personalized therapies for children with NAFLD in the future.  
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Table 1. Demographic, Anthropometric, and Laboratory Values for Children with Zone 1 
and Zone 3 Steatosis 
Characteristics Total Zone 1 Zone 3 P-value 
N (%) or mean (SD) N=390 N=146 N=244  
Demographics 
    
     Age (years) 13.3 (2.9) 10.8 (2.1) 14.7 (2.1) <0.001 
     Sex     
          Male 274 (70.2) 111 (76.0) 163 (66.8) 0.070 
          Female 116 (29.8) 35 (24.1) 81 (33.2)  
     Ethnicity     
          Hispanic 248 (63.9) 108 (75.0) 140 (57.6) 0.001 
          Non-Hispanic 140 (36.0) 37 (25.0) 103 (42.4)  
Anthropometric 
    
     Height (cm) 160.9 (14.4) 149.9 (12.9) 167.6 (10.6) <0.001 
     Weight (kg) 86.5 (26.5) 67.9 (20.1) 97.7 (23.5) <0.001 
     BMI (kg/m2) 32.7 (6.6) 29.6 (5.5) 34.5 (6.5) <0.001 
     BMI Z-score 2.25 (0.42) 2.22 (0.41) 2.26 (0.43) 0.434 
     Waist Circumference (cm) 104.6 (15.6) 96.4 (13.9) 109.5 (14.5) <0.001 
     Systolic BP (mmHg) 122 (14) 117 (12) 125 (14) <0.001 
     Diastolic BP (mmHg) 68 (10) 65 (9) 70 (10) <0.001 
Laboratory Values 
    
     AST (U/L) 53 (37) 56 (34) 52 (38) 0.017 
     ALT (U/L) 86 (64) 89 (67) 85 (62) 0.582 
     GGT (U/L) 41 (30) 37 (24) 43 (33) 0.123 
     Triglycerides (mg/dL) 150 (89) 125 (64) 164 (99) <0.001 
     LDL (mg/dL) 100 (30) 99 (26) 101 (31) 0.968 
     HDL (mg/dL) 39 (9) 40 (10) 39 (9) 0.064 
     Total Cholesterol (mg/dL) 168 (37) 165 (30) 170 (40) 0.233 
     Glucose (mg/dL) 87 (14) 86 (9) 88 (16) 0.975 
     Insulin (µU/mL) 34 (31) 25 (19) 39 (36) <0.001 
Demographic and anthropometric continuous parameters using T-test, category parameter using 
Chi-square test. Laboratory continuous parameters using Wilcoxon Rank test. 
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Table 2. Histological Characteristics for Children with Zone 1 and Zone 3 Steatosis 
Liver Histology Total Zone 1 Zone 3 P-value 
N (%) N=390 N=146 N=244  
Steatosis 
    
     5-33% 127 (32.6) 50 (34.5) 77 (31.6) 0.844 
     34-66% 150 (38.5) 54 (36.9) 96 (39.3)  
     ≥66% 113 (29.0) 42 (28.8) 71 (29.1)  
Portal Inflammation 
    
     None 45 (11.5) 5 (3.4) 40 (16.4) <0.001 
     Mild 285 (73.1) 105 (71.9) 180 (73.8)  
     More than mild 60 (15.4) 36 (24.7) 24 (9.8)  
Lobular inflammation 
    
     <2 under 20x 226 (57.9) 81 (55.5) 145 (59.4) 0.444 
     2-4 under 20x 139 (35.6) 57 (39.0) 82 (33.6)  
     >4 under 20x 24 (6.2) 7 (4.8) 17 (7.0)  
Ballooning    
    
     None 233 (59.7) 104 (71.2) 129 (52.9) <0.001 
     Few 106 (27.2) 36 (24.6) 70 (28.7)  
     Many 51 (13.1) 6 (4.1) 45 (18.4)  
Fibrosis 
    
     None 147 (37.8) 27 (18.6) 120 (49.1) <0.001 
     Mild, Zone 3 perisinusoidal 32 (8.2) 2 (1.4) 30 (12.3)  
     Moderate, Zone 3 perisinusoidal 22 (5.7) 1 (0.7) 21 (8.6)  
     Portal/periportal only 115 (29.6) 91 (62.8) 24 (9.8)  
     Zone 3 and periportal 43 (11.1) 5 (3.5) 38 (15.6)  
     Bridging Fibrosis 30 (7.7) 19 (13.1) 11 (4.5)  
NAS Score 4.0 (1.4) 3.7 (1.3) 4.1 (1.5) 0.014 
Diagnosis 
    
     NAFLD, not NASH 121 (31.0) 21 (14.4) 100 (40.9) <0.001 
     Borderline NASH: Zone 3 pattern 61 (15.6) 0 (0.0) 61 (25.0)  
     Borderline NASH: Zone 1 pattern 125 (32.1) 116 (79.5) 9 (3.7)  
     Definite NASH 83 (21.3) 9 (6.2) 74 (30.3)  
All parameters using Mantel-Haenszel Chi-Square Test 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 3. Characteristics of Children with Zone 3 Steatosis and Mild Central or Portal 
Fibrosis 
Characteristics Total Central Portal P-value 
N (%) or mean (SD) N=75 N=51 N=24  
Demographic 
    
     Age (years) 15.2 (2.2) 15.7 (1.8) 14.2 (2.7) 0.0142 
     Sex     
          Male 50 (66.7) 36 (70.6) 14 (58.3) 0.2936 
          Female 25 (33.3) 15 (29.4) 10 (41.7)  
     Ethnicity      
          Hispanic 36 (48.6) 23 (46.0) 13 (54.2) 0.5106 
          Non-Hispanic 38 (51.4) 27 (54.0) 11 (45.8)  
Anthropometric 
    
     BMI (kg/m2) 35.1 (0.7) 35.0 (0.9) 35.4 (1.4) 0.8395 
     BMI Z-score 2.3 (0.4) 2.25 (0.4) 2.38 (0.4) 0.2238 
Laboratory Values 
    
     AST (U/L) 52 (45) 60 (52) 35 (13) <0.0001 
     ALT (U/L) 84 (56) 97 (60) 56 (32) 0.0003 
     GGT (U/L) 44 (26) 44 (28) 42 (20) 0.8602 
Liver Histology 
    
     Steatosis     
          5-33% 20 (26.7) 10 (19.6) 10 (41.7) 0.0778 
          34-66% 34 (45.3) 25 (49.0) 9 (37.5)  
          >67% 21 (28.0) 16 (31.4) 5 (20.8)  
     Portal Inflammation     
          None 13 (17.3) 11 (21.6) 2 (8.3) 0.0112 
          Mild 56 (74.7) 39 (76.5) 17 (70.8)  
          More than mild 6 (8.0) 1 (1.9) 5 (20.9)  
     Lobular Inflammation     
          <2 under 20x 42 (56.0) 26 (50.9) 16 (66.7) 0.1712 
          2-4 under 20x 29 (38.7) 21 (41.2) 8 (33.3)  
          >4 under 20x 
     Ballooning 
4 (5.3) 4 (7.8) 0 (0.0)  
          None 35 (46.7) 19 (37.2) 16 (66.7) 0.0020 
          Few 22 (29.3) 14 (27.4) 8 (33.3)  
          Many 18 (24.0) 18 (35.3) 0 (0)  
     Diagnosis     
          NAFLD, not NASH 16 (21.3) 1 (1.9) 15 (62.5) <0.0001 
          Borderline NASH: Zone 3 Pattern 25 (33.3) 22 (43.1) 3 (12.5)  
          Borderline NASH: Zone 1 Pattern 4 (5.3) 0 (0.0) 4 (16.7)  
          Definite NASH 30 (40.0) 28 (54.9) 2 (8.3)  
Demographic and anthropometric continuous parameters using T-test, category parameter using 
Chi-square test. Laboratory continuous parameters using Wilcoxon Rank test. 
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Supplemental Table 1. Demographic, Anthropometric, and Laboratory Values for All 
Children and for Children with Panacinar and Azonal Steatosis 
Characteristics Overall Panacinar Azonal 
N (%) or mean (SD) N=776 N=327 N=59 
Demographics 
   
     Age (years) 12.8 (2.7) 12.3 (2.5) 12.7 (2.4) 
     Sex    
          Male 550 (70.9) 236 (72.2) 40 (67.8) 
          Female 226 (29.1) 91 (27.8) 19 (32.2) 
     Ethnicity    
          Hispanic 521 (67.3) 232 (70.9) 41 (69.5) 
          Non-Hispanic 253 (32.7) 95 (29.1) 37 (30.5) 
Anthropometric 
   
     Height (cm) 159.2 (13.8) 157.1 (13.0) 159.4 (12.3) 
     Weight (kg) 83.6 (25.6) 79.2 (22.8) 88.4 (30.8) 
     BMI (kg/m2) 32.3 (6.3) 31.5 (5.6) 34.0 (7.9) 
     BMI Z-score 2.25 (0.44) 2.23 (0.47) 2.33 (0.41) 
     Waist Circumference (cm) 103.0 (15.4) 102.0 (14.6) 108.3 (18.7) 
     Systolic BP (mmHg) 121 (14) 121 (14) 119 (13) 
     Diastolic BP (mmHg) 68 (10) 68 (9) 68 (10) 
Laboratory Values 
   
     AST (U/L) 64 (49) 75 (57) 74 (61) 
     ALT (U/L) 107 (89) 128 (104) 122 (111) 
     GGT (U/L) 46 (35) 50 (36) 53 (56) 
     Triglycerides (mg/dL) 151 (88) 152 (87) 154 (85) 
     LDL (mg/dL) 99 (30) 99 (30) 96 (31) 
     HDL (mg/dL) 39 (10) 39 (10) 39 (10) 
     Total Cholesterol (mg/dL) 168 (38) 168 (39) 167 (38) 
     Glucose (mg/dL) 72 (37) 70 (42) 67 (34) 
     Insulin (µU/mL) 34 (41) 33 (45) 43 (70) 
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Supplemental Table 2. Histological Characteristics for All Children and Children with 
Panacinar and Azonal Steatosis 
Liver Histology Overall Panacinar Azonal 
N (%) N=776 N=327 N=59 
Steatosis 
   
     5-33% 213 (27.4) 55 (16.8) 31 (52.5) 
     34-66% 234 (30.2) 62 (19.0) 22 (37.3) 
     ≥66% 329 (42.4) 210 (64.2) 6 (10.2) 
Portal Inflammation 
   
     None 70 (9.0) 23 (7.0) 2 (3.4) 
     Mild 578 (74.5) 248 (75.8) 45 (76.3) 
     More than mild 128 (16.5) 56 (17.1) 12 (20.3) 
Lobular inflammation 
   
     <2 under 20x 430 (55.4) 161 (49.2) 42 (71.2) 
     2-4 under 20x 295 (38.0) 140 (42.8) 16 (27.1) 
     >4 under 20x 51 (6.6) 26 (8.0) 1 (1.7) 
Ballooning    
   
     None 447 (57.6) 181 (55.4) 33 (55.9) 
     Few 218 (28.1) 98 (30.0) 14 (23.7) 
     Many 111 (14.3) 48 (14.7) 12 (20.3) 
Fibrosis 
   
     None 246 (31.9) 82 (25.2) 17 (29.3) 
     Mild, Zone 3 perisinusoidal 53 (6.9) 19 (5.8) 2 (3.4) 
     Moderate, Zone 3 perisinusoidal 34 (4.4) 9 (2.8) 3 (5.2) 
     Portal/periportal only 218 (28.2) 95 (29.2) 8 (13.8) 
     Zone 3 and periportal 116 (15.0) 65 (20.0) 8 (13.8) 
     Bridging Fibrosis 93 (12.0) 48 (14.8) 15 (25.9) 
     Cirrhosis 12 (1.6) 7 (2.2) 5 (8.6) 
NAS Score 4.2 (1.4) 4.6 (1.4) 3.5 (1.2) 
Diagnosis 
   
     NAFLD, not NASH 220 (28.4) 77 (23.5) 22 (37.3) 
     Borderline NASH: Zone 3 pattern 131 (16.9) 60 (18.3) 10 (16.9) 
     Borderline NASH: Zone 1 pattern 232 (29.9) 99 (30.3) 8 (13.6) 
     Definite NASH 193 (24.9) 91 (27.8) 19 (32.2) 
 
